Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

RNS System LGS Feasibility Study

NCT: NCT05339126 · ACTIVE_NOT_RECRUITING

NCT IDNCT05339126
StatusACTIVE_NOT_RECRUITING
Start Date2022-10-04
Completion2026-12-31
SponsorNeuroPace (INDUSTRY)
First posted
Last updated

Brief Summary

To generate preliminary safety and effectiveness data for brain-responsive neurostimulation of thalamocortical networks as an adjunctive therapy in reducing the frequency of generalized seizures in individuals 12 years of age or older with Lennox Gastaut Syndrome (LGS) who are refractory to antiseizure medications. The intent is to determine the feasibility and the optimal design of a subsequent pivotal study in order to expand the indication for use for the RNS System as a treatment for patients with medically intractable LGS.

Frequently Asked Questions

What is RNS System LGS Feasibility Study?

RNS System LGS Feasibility Study is a clinical trial registered under NCT05339126. Current status: ACTIVE_NOT_RECRUITING.

What is the status of NCT05339126?

The current status of NCT05339126 (RNS System LGS Feasibility Study) is: ACTIVE_NOT_RECRUITING.

When did RNS System LGS Feasibility Study start?

RNS System LGS Feasibility Study started on 2022-10-04.

Related Devices

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.